Accurate. Earlier. Detection.
Amplified Sciences is focused on providing innovative diagnostic tests that enable earlier detection, risk stratification, and monitoring of challenging diseases.

Jo is Founder and serves as Chief Scientific Officer of Amplified Sciences. He is currently a Professor in the Purdue University College of Pharmacy, and is the inventor of the proprietary chemistry platform technology. A subject matter thought leader, Dr. Davisson holds numerous publications in the field, serves on prestigious NIH grant review committees, and has extensive experience as a private consultant in the life sciences industry. He has been directly involved in multiple early startup technology companies including Aseda Sciences and Tienta Sciences. Dr. Davisson’s areas of expertise include discovery, scientific development strategies, novel biochemistry technologies, small molecule development, grant strategies, and collaboration partner development.

Diana is an accomplished and recognized serial life science entrepreneur with over 25 years of experience in both large corporate and small entrepreneurial environments. Throughout her career, she has successfully driven organizational growth, developed and implemented strategic business plans, raised capital, launched novel life science products, and directed successful teams. Prior to taking helm as CEO of Amplified Sciences, Diana served as an Entrepreneur in Residence at the Purdue Foundry supporting several early stage startups. Early in her career, she worked for Eli Lilly for over 15 years in a variety of general management leadership roles in product management, marketing, finance, sales, and operations. In 2010, Diana co-founded Pearl Pathways (exit to Versiti in 2023) where she led the company as President and CEO and oversaw all strategic plans and business operations. Pearl Pathways is a life science product development consulting company focused on expediting regulatory pathways, building and enhancing quality management systems, delivering AHHRPP accredited IRB clinical research review services, and executing clinical trials through a niche CRO offering. Under her leadership she was able to scale the company to a multimillion-dollar company with fifteen employees and dozens of consultant partners. In 2018 she sold her interest in Pearl Pathways to pursue the startup of another life science product company.

Mike Poderycki is the Director of Research and Technology at Amplified Sciences. He earned his PhD in Cell Biology at UCLA studying ribonucleoprotein assembly and completed his postdoctoral training at the La Jolla Institute for Immunology. Mike subsequently led R&D projects at Life Technologies in San Diego, commercializing tools designed to facilitate cell line development and genome editing. He then joined a preclinical cell therapy initiative at Cook Group in West Lafayette before moving to Thermo Fisher as Senior R&D Manager for molecular biology and genome editing. After 9 years in the biotechnology and medical device industries, Mike joined Purdue University to create and lead the Bindley Bioscience Center-affiliated Innovation Accelerator. He served as an industry liaison and led various commercialization and entrepreneurship programs including the Purdue University hub of the federal Biomedical Advanced Research and Development Authority (BARDA) DRIVe Accelerator Network. Mike now leads the Amplified Sciences R&D team on its mission to translate cutting-edge technology into novel diagnostics that can fill pressing and unmet clinical needs.

John brings over 20 years of experience working in Market Access and cross functionally with commercial functions for Medical Device and Diagnostics companies, with significant roles at Roche Diagnostics, Ventana Medical Systems, WL Gore, Exact Sciences, and Lucid Diagnostics. John’s notable accomplishments include leading a team to expand coverage for a new technology from 10 million to over 100 million lives. He has also secured a Centers for Medicare & Medicaid Services (CMS) National Coverage Determination, which broadened the market for a novel diagnostic test from 500,000 to over 5 million patients. Additionally, John has obtained in-network contracts with numerous payers and managed revenue cycle activities that grew products to $25 million. He has worked across public and private payers, secured numerous AMA Category 1 CPT codes and Proprietary Laboratory Analysis (PLA) codes, and is an expert at navigating the CMS payment process to finalize reimbursement rates. John has participated in numerous product launches throughout his career, most notably, Exact Sciences’ Cologuard and Lucid Diagnostics’ Esoguard.

Rebecca is the Operations Manager at Amplified Sciences. A love of science has been at the core of every part of her career and she has thrived in environments where science and business overlap. Rebecca received her Bachelor of Science in Biology from Indiana University and PhD in Microbiology and Microbial Pathogenesis from Washington University where she studied the mechanism of toxin production in the Bordetellae. Rebecca worked at both Washington University in St. Louis and Indiana University in a variety of technology transfer positions where she was involved in patenting and commercializing new technologies. She joined the gene therapy startup Genezen as an early employee and as Chief Business Officer, helped grow the company from a virtual business to a GMP brick-and-mortar manufacturing facility. In her current role at Amplified Sciences, Rebecca draws on her varied background to help business and lab operations run smoothly.

Rapid and clinical diagnostics researcher with 10+ years of lab experience in biosensing and analyte detection technology translation. Kaleb began their research journey in a Biosensing lab as an undergraduate, and earned their BS in Biological Engineering from the University of Florida in May 2016, accompanied by the prestigious Weil Engineering Leadership Award. That same year, Kaleb achieved first place in the Undergraduate Agricultural and Biological Engineering Poster Competition and secured second place in a Global Health Case Competition and a Business Plan Competition at the University of Florida.

Dr. Thomas brings more than 10 years of experience in the biotech industry including synthesis of molecules, fit-to purpose assay development, large-molecule development, receptor targeted drug delivery, complex disease model development, and her expertise in near infrared (NIR) fluorescence imaging to the company. Prior to joining Amplified Sciences, Thomas was a senior scientist at Quince Therapeutics, a biotech startup focused on advancing innovative precision therapeutics for debilitating and rare diseases where she worked on the development of pharmacokinetics (PK) and antidrug antibody assay (ADA) development. Thomas received her Ph.D in organic chemistry from Indian Institute of Science where she worked on the design and synthesis of novel artificial transcription factors and characterization of their binding to DNA using spectroscopic and biochemical techniques. Thereafter, she accepted a Postdoctoral fellowship in Chemistry and Bioengineering from the Massachusetts Institute of Technology, where she worked on the development of nonviral vectors for gene and siRNA therapies.

Kaitlyn Varela is a Senior Scientist at Amplified Sciences. She earned her B.S. in Biochemistry and her PhD in Chemistry from UTSA. Her doctoral research, which has been nationally recognized by prominent organizations such as Merck, Dow, and Johnson & Johnson, focused on two key areas: (i) studying how a plant produces the antimalarial medicine artemisinin through a cascade reaction involving molecular oxygen, and (ii) exploring the anticancer and antiviral properties of arteannuin B by blocking cysteine proteases. Kaitlyn has published four first-author research articles in the Journal of Natural Products (2020, 2021, 2022, and 2023) based on her work using organic chemistry to address biological problems. In 2021, she was awarded both the National Science Foundation Graduate Research Fellowship Program (NSF GRFP) and Ford Foundation Predoctoral Fellowships.